Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial

• Published in: Circulation. Cardiovascular interventions Vol. 9; no. 2; p. e003145
• Main Authors: Han, Yaling, Xu, Bo, Xu, Kai, Guan, Changdong, Jing, Quanmin, Zheng, Qiangsun, Li, Xueqi, Zhao, Xianxian, Wang, Haichang, Zhao, Xuezhong, Li, Xiaoyan, Yu, Pengfei, Zang, Hongyun, Wang, Zhifang, Cao, Xuebin, Zhang, Jun, Pang, Wenyue, Li, Jing, Yang, Yuejin, Dangas, George D
• Format: Journal Article
• Language: English
• Published: United States American Heart Association, Inc 01.02.2016
• Subjects: Absorbable Implants; Aged; Antibiotics, Antineoplastic - administration & dosage; Aspirin - administration & dosage; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention - instrumentation; Platelet Aggregation Inhibitors - administration & dosage; Prospective Studies; Sirolimus - administration & dosage; Ticlopidine - administration & dosage; Ticlopidine - analogs & derivatives; clinical trial; drug-eluting stents; polymers; myocardial infarction; hemorrhage
• ISSN: 1941-7640; 1941-7632
• DOI: 10.1161/CIRCINTERVENTIONS.115.003145

BACKGROUND—There are no reports on a large-scale randomized trial exploring optimal dual antiplatelet therapy (DAPT) duration after biodegradable polymer sirolimus-eluting stent implantation. We sought to report the outcomes of a randomized substudy of the prospective Evaluate Safety and Effectiveness of the Tivoli DES and the Firebird DES for Treatment of Coronary Revascularization (I-LOVE-IT 2) trial. METHODS AND RESULTS—In the prospective noninferiority randomized I-LOVE-IT 2 trial, 1829 patients allocated to the biodegradable polymer sirolimus-eluting stent group were also randomized to receive either 6-month (n=909) or 12-month DAPT (n=920). The primary end points of this noninferiority substudy were 12-month target lesion failure (composite of cardiac death, target vessel myocardial infarction or clinically indicated target lesion revascularization), and the major secondary end points were 12-month net adverse clinical and cerebral events (composite of all-cause death, all myocardial infarction, stroke, or major bleeding [Bleeding Academic Research Consortium type ≥3]). The 12-month target lesion failure in 6-month DAPT group was comparable with the 12-month DAPT group (6.8% versus 5.9%; difference and 95% confidence interval, 0.87% [−1.37% to 3.11%], P for noninferiority=0.0065). Further follow-up at 18 months showed that incidence of target lesion failure and net adverse clinical and cerebral events were similar between the 2 groups (7.5% versus 6.3%, log-rank P=0.32; 7.8% versus 7.3%, log-rank P=0.60; respectively), as well as their individual end point components. CONCLUSIONS—This study indicated noninferiority in safety and efficacy of 6-month versus 12-month DAPT after implantation of a novel biodegradable polymer sirolimus-eluting stent. CLINICAL TRIAL REGISTRATION—URLhttp://www.clinicaltrials.gov. Unique identifierNCT01681381.